Plain-English translation of NCT06297226 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Myeloma research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new treatment called for multiple myeloma that has not responded to or has come back after previous treatments. The medication works by taking your own immune cells, modifying them in a lab to help them fight myeloma, and then putting them back into your body. Researchers want to see how well this treatment works and how safe it is for patients like you.
Multiple myeloma is a blood cancer that often becomes harder to treat after patients have tried several standard therapies. This medication was designed to target a specific protein on myeloma cells, offering a new option for people whose cancer has stopped responding to other treatments.
You likely qualify if…
You likely don't qualify if…
If you join this trial, your own immune cells will be collected through a process called leukapheresis (similar to donating blood). Those cells will then be sent to a lab where they are modified to recognize and fight myeloma. While your cells are being prepared, you may receive other treatments. Once your modified cells are ready, you will receive them back through an infusion, and the research team will closely monitor you for side effects and how well the treatment is working.
AI-generated summary from trial data · Jun 19, 2026 · Not medical advice
United States